Belief BioMed

Focus: Belief BioMed is an early-stage Chinese biotechnology company focused on AAV-delivered gene therapies for severe genetic and degenerative diseases. Founded in 2024, it operates at pre-clinical to early clinical stages with minimal public visibility.

Gene Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Belief BioMed

AI assessmentNot Hiring

No open roles listed right now. Follow Belief BioMed to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BBM-A101

Knee Osteoarthritis

Phase 1

Clinical Trials (1)

NCT07198555A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of BBM-A101 in the Treatment of Knee Osteoarthritis.

Phase 1

Help build intelligence for Belief BioMed

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at a newly founded gene therapy company with potential to shape its culture and early scientific direction
Focus on AAV gene therapy addresses large unmet needs in muscular dystrophy and osteoarthritis with significant commercial potential
Early-stage positioning offers accelerated learning and direct impact on drug development decisions vs. large pharma bureaucracy

Watch Out For

Pre-revenue status with undisclosed funding presents extreme financial and runway uncertainty; company viability unproven
Zero active job openings and no public hiring activity signal minimal team build-out or uncertain near-term headcount plans
Early pipeline (Phase 1/2 only) with no published data or third-party validation of scientific approach; execution risk is high

Generated by Claude from Belief BioMed's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BBM-D101

Duchenne Muscular Dystrophy

Phase 1/2

Clinical Trials (1)

NCT07058662A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of BBM-D101 in the Treatment of Duchenne Muscular Dystrophy.

Phase 1/2

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo